Vaccines

Primary tabs

Thu, 2015-01-08 20:48 — mdmcdonald

Information on vaccines to counter Ebola and other diseases

The Mission of this group is to follow the development of vaccines and other medications to counter Ebola and other diseases.

Add Content to this group

Click to add a new Group Post Simple to this group
Click to add a new Group Post Simple w Images to this group
Click to add a new Group Post to this group
Click to add a new PRIVATE Group Post to this group
Click to add a new TASK to this group

Members

Kathy Gilbeaux

mdmcdonald

MDMcDonald_me_com

mike kraft

Subscribe to group

Email address for group

vaccines_global@m.resiliencesystem.org

The Race for the Ebola Vaccine

Wed, 2015-01-07 10:26 — mike kraft

THE DAILY BEAST by Abby Haglage Jan. 7, 2015

...Although a few smaller companies have become involved in the race for a vaccine, three major pharmaceutical makers are taking the lead—each pursuing a different vaccine. The trials are unprecedented for a variety of reasons, including the rapid timeline (trials of this nature generally take three to four years).

Steve Parsons-WPA Pool/Getty Images

Each individual race involves an unusual collaboration between researchers, manufacturers, and public-health entities. Together, the teams are working 24 hours a day for a product that promises much higher risk than it does profit.

Here’s what you need to know about the Ebola vaccine front-runners.

Read complete story.

http://www.thedailybeast.com/articles/2015/01/07/the-race-for-the-ebola-vaccine.html

Country / Region Tags:

General Topic Tags:

Problem, Solution, SitRep, or ?:

Solutions

Situation Report

Read more about The Race for the Ebola Vaccine
Log in or register to post comments

J&J, Bavarian Nordic start clinical tests in Ebola vaccine race

Tue, 2015-01-06 09:52 — mike kraft

REUTERS by Ben Hirschler Jan. 6, 2015
LONDON --Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic, making it the third such shot to enter human testing.

The initiation of the Phase I study in Britain, which had been expected about now, marks further progress in the race to develop a vaccine against a disease that has killed more than 8,000 people in West Africa since last year.

Two other experimental vaccines, one from GlaxoSmithKline and a rival from NewLink and Merck, are already in clinical development. However, the J&J vaccine offers a different approach, since it involves two separate injections.